GlassScriptPhysician profile
Kenneth Carter
NPI 1912901331
$9,011.86
in general payments reported to CMS, 2019-2025
30 companies · $5,580 in 2025
The $5,580 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $83.45 · 2021: $436 · 2022: $679 · 2023: $32.21 · 2024: $2,003 · 2025: $5,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Food and Beverage | $614.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,000.00 | 2024-2025 | Bovine Collagen |
| Avion Pharmaceuticals | $352.54 | 2021-2022 | |
| Abbvie INC. | $323.38 | 2019-2023 | Lo Loestrin Fe |
| Aspira Women'S Health INC | $244.26 | 2022-2024 | Ova1 |
| Stryker Corporation | $116.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.29 | 2024-2025 | |
| Mylan Pharmaceuticals INC. | $94.52 | 2020-2022 | |
| Biogen, INC. | $87.70 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $82.69 | 2021-2025 | |
| Astellas Pharma US INC | $78.71 | 2024-2025 | Veozah |
| Coopersurgical, INC. | $77.55 | 2019-2025 | Sos, Ally II Ups |
| Sumitomo Pharma America, INC. | $49.16 | 2025 | Myfembree |
| Channel Medsystems, INC. | $41.15 | 2022 | |
| Hologic Sales and Service, LLC | $35.95 | 2022-2025 | Aptima |
| Exact Sciences Corporation | $33.40 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $32.02 | 2022 | |
| Millicent US INC | $31.88 | 2025 | Femlyv, Intrarosa |
| Ethicon US, LLC | $25.40 | 2022 | |
| Shield Therapeutics INC | $24.16 | 2024 | |
| Scynexis, INC. | $23.24 | 2022 | |
| Roche Diagnostics Corporation | $22.86 | 2020 | |
| Octapharma USA, INC. | $18.76 | 2025 | Fibryga |
| Exeltis, USA INC. | $17.60 | 2025 | Slynd |
| Minerva Surgical, INC | $17.00 | 2025 | |
| Evofem Biosciences, INC. | $14.51 | 2021 | |
| Pfizer INC. | $14.35 | 2021 | |
| Agile Therapeutics, INC. | $14.12 | 2022 | |
| Allergan, INC. | $14.03 | 2019 | |
| Dentsply Sirona INC | $12.69 | 2019 | |
| Lupin INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.